

腎疾患政策研究事業事前評価委員会名簿

(○：委員長)

○

氏名	小山 哲夫
所属・役職	筑波大学名誉教授
専門分野	腎臓学
業績・実績	Glomerulonephritis associated with MRSA infection: A possible role of bacterial Int 1995; 47:207-216 (Koyama A, Kobayashi M, Yamaguchi N et al.
	A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity.(Koyama A, Yamagata K, Makino H et al. Clin Exp Nephrol. 2009 Dec; 13(6):633-50
	Risk factors for chronic kidney disease in a community-based population: a 10-year follow up study. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Koyama A. 2007 Jan; 71; (2): 159-66

氏名	相川 厚
所属・役職	学校法人東邦大学・名誉教授
専門分野	腎移植、腎臓学、泌尿器科
業績・実績	Kobayashi D, Ganse M, Shinoda T, Hamada C, Hara S, Aikawa A, Iino Y, Komatsu Y. : A survey on the association between patient activation and quality of life among patients with chronic kidney disease in Japan. J Nephrol. 2025 Jun;38(5):1427-1436.
	Hasegawa K, Motoyama O, Shishido S, Aikawa A.: Mineral disorders in pediatric pre-emptive kidney transplantation. Pediatr Int. 2019 Jun;61(6):587-594.
	Aikawa A, Ohara T, Arai K, Hadano T, Kawamura T, Sugiyama K, Muramatsu M, Itabashi Y, Kawada N, Kanai T, Hasegawa A.: Clinical outcome and accommodation in ABO incompatible kidney transplantation. Clin Transpl. 2004:135-42.

氏名	下條 文武
所属・役職	新潟大学 名誉教授
専門分野	腎臓内科
業績・実績	Long-term efficacy and safety of difelikefalin in moderate-to-severe pruritus in Japanese hemodialysis patients: a 52-week open-label extension period of a phase 3 trial. Narita I, Tsubakihara Y, Takahashi N, Ebata T, Uchiyama T, Marumo M, Okumura S, Gejyo F and MR13A-4 Trial Investigators. Renal Replacement Therapy 2024, 10: 42, 19 July
	Macromolecular crowding and supersaturation protect hemodialysis patients from the onset of dialysis-related amyloidosis. Nakajima K, Yamaguchi K, Noji M, Aguirre C, Ikenaka K, Mochizuki H, Zhou L, Ogi H, Ito T, Narita I, Gejyo F, Naiki H, Yamamoto S, Goto Y. Nature Communications. 2022 Oct 3. doi:10.1038/s41467-022-33247-3
	"Efficacy and safety of difelikefalin in Japanese patients with moderate to severe pruritus receiving hemodialysis: A randomized clinical trial. Narita I, Tsubakihara Y, Uchiyama T, Okamura S, Oya N, Takahashi N, Gejyo F, MR13A9-4 Trial Investigators. JAMA Network Open. 2022 May 2;5(5): e2210339. doi:10.1001"

氏名	富野 康日己
所属・役職	医療法人社団松和会・理事長
専門分野	腎臓内科学
業績・実績	" My journey on the path to understanding IgA nephropathy: From bench to bedside. Tomino Y. Nephrology. 2024;29 (Suppl. 2): 51-54"
	IgA nephropathy: Beyond the Half-Century. Shimizu Y, Tomino Y, Suzuki Y. Medicina 2024;60:54
	「尿検査のみかた、考えかた」改訂2版。富野康日己（監修）、金子一成、鈴木祐介（編集）。中外医学社、2024年10月25日

氏名	西崎 祐史
所属・役職	順天堂大学 医学部医学教育研究室・教授
専門分野	医学教育 一般内科
業績・実績	Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, Kimura K, Ozaki Y, Murohara T, Ueshima K, Kuwabara Y, Tanaka-Mizuno S, Yanagisawa N, Sato T, Daida H; RESPECT-EPA Investigators. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024 Aug 6;150(6):425-434.
	Nishizaki Y, Miyauchi K, Iwata H, Inoue T, Hirayama A, Kimura K, Ozaki Y, Murohara T, Ueshima K, Kuwabara Y, Tanaka-Mizuno S, Yanagisawa N, Sato T, Daida H. Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study. Am Heart J. 2023 Mar;257:1-8.
	Hashimoto H, Nojiri S, Takeda T, Urasaki W, Nishizaki Y, Nagahara A, Aoki S. Examining associations of digestive system cancer with hypertension and diabetes using network analysis in older patients. Sci Rep. 2025 Feb 22;15(1):6458.